LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans (AHIP) … [Read more…]
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in … [Read more…]
Immersive experience for privacy and security programs like HIPAA ATLANTA–(BUSINESS WIRE)–#BlackTalonSecurity–Information privacy and security has increased in significance for companies and organizations of all sizes. However, as the toll information losses and cyberattacks take on companies are fully realized, the stakes are higher than ever for those responsible for protecting critical data and infrastructure. To … [Read more…]
WASHINGTON–(BUSINESS WIRE)–Gallup’s latest State of the Global Workplace Report finds that, despite more than two years of the pandemic, U.S. and Canadian workers seemed to rebound in 2021. Employees reported higher life evaluations than the previous year and declines across several negative emotions. In 2021, 33% of U.S. and Canadian employees were engaged at work … [Read more…]
CHICAGO–(BUSINESS WIRE)–MERGE, a premium storytelling and technology company, announced today that it has been named to the MM&M 2022 Agency 100. MERGE advanced four spots to number 15 in 2022. The Agency 100 recognizes the top agencies, from boutique to multinational, in medical marketing and communications, putting MERGE among the industry elite. Nominees are selected … [Read more…]
First presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose No serious adverse events, treatment discontinuations, deaths or dose-limiting toxicity events related to 177Lu-FAP-2286 observed Confirmed partial response in one patient who completed six administrations of … [Read more…]
Grant will support Company’s first US-based clinical trial, to be conducted at Baylor College of Medicine New Immunopheresis® therapeutic molecular ligand-capture platform is designed to activate endogenous antitumor pathways by removing factors shed by cancer cells that suppress immune response and promote cancer growth The Company’s fourth clinical trial seeks to provide important safety, efficacy, … [Read more…]
Field trials consistently demonstrate a 15% yield improvement in fruits and vegetables DAVIS, Calif.–(BUSINESS WIRE)–BioConsortia, Inc. and The Mosaic Company (NYSE: MOS) have entered into a new agreement to distribute BioConsortia’s new microbial biostimulant in Asia. The new biostimulant BEC69 is branded as ZAFFRE™ in North America, and is expected to provide growers with significant … [Read more…]
Executive Joins Leadership Team as City of Hope Builds National System Focused on Transforming Cancer Research and Treatment LOS ANGELES–(BUSINESS WIRE)–City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that Philip Okala, chief operating officer at the University of Pennsylvania Health System, will join the organization … [Read more…]
BOULDER, Colo.–(BUSINESS WIRE)–Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. announced the closing of a $11.4 million financing led by Telegraph Hill Partners (“THP”), a life science venture capital and growth equity firm based in San Francisco, … [Read more…]
